other material
confidence high
sentiment neutral
materiality 0.80
Inhibikase raises $50M through ATM sale of 25M shares to RA Capital for PAH study
Inhibikase Therapeutics, Inc.
- Sold 25,000,000 shares to RA Capital Management for $50M gross proceeds via ATM facility.
- Proceeds will fund operations through topline data readout from Phase 3 IMPROVE-PAH Part B.
- Shares sold under effective shelf registration (Form S-3) and ATM prospectus supplement.
- Company is clinical-stage developing IKT-001 for Pulmonary Arterial Hypertension.